Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Harry Thompson

Surgery Champaign, IL Medical Doctor

NPI 1083753214 CMS profile 185138

413 E University Ave, Champaign, IL 61820

Open in the dashboard

General payments

$1,833

28 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Harry Thompson of Champaign, IL is reported in the CMS Open Payments database as having received $1,833 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $120 1
2023 General $260 2
2022 General $298 3
2021 General $607 7
2020 General $176 6
2019 General $372 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harry Thompson
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Harry Thompson were reported at $0. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Harry Thompson Surgery median Middle half National median
2019 $372 $253 $82–$1,521 $163
2020 $176 $131 $40–$706 $114
2021 $607 $168 $50–$904 $132
2022 $298 $224 $76–$1,218 $149
2023 $260 $253 $82–$1,255 $160
2024 $120 $279 $90–$1,381 $164
2025 $0 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $512 11 payments
  2. AstraZeneca Pharmaceuticals LP $416 6 payments
  3. Amgen Inc. $354 3 payments
  4. Dexcom, Inc. $170 3 payments
  5. Boston Scientific Corporation $137 1 payment
  6. Biohaven Pharmaceuticals, Inc. $122 1 payment
  7. ITI, Inc. $87 1 payment
  8. Lilly USA, LLC $18 1 payment
  9. Pfizer Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,827 27 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2024
  1. Ozempic $421 10 payments
  2. Repatha $354 3 payments
  3. FARXIGA $304 4 payments
  4. DEXCOM G6 TRANSMITTER $170 3 payments
  5. WATCHMAN Access System $137 1 payment
  6. RYBELSUS $130 3 payments
  7. NURTEC ODT $122 1 payment
  8. BREZTRI $97 1 payment
  9. CAPLYTA $87 1 payment
  10. VERZENIO $18 1 payment
  11. Other $64 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

219

Median for General Surgery: 59

Drug cost

$7,925

Median for General Surgery: $393

Branded share of claims

33.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tradjenta Linagliptin Brand 11 $4,955
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $495
Memantine Hcl Er Memantine Hcl Brand 12 $467
Atorvastatin Calcium Generic 27 $435
Enalapril Maleate Generic 25 $370
Amlodipine Besylate Generic 28 $302
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 11 $246
Losartan Potassium Generic 18 $236
Omeprazole Generic 16 $179
Potassium Chloride Generic 12 $113

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record